Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.51 |
| ▸ | HTR2C | P28335 | 4/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25707143 | 1.00 | HTR2A (0.51) | HTR2AHTR2CTAAR1GNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL25240543 | 0.99 | HTR2A (0.50) | HTR2AHTR2CTAAR1GNAI3GNAO1 | |
| SCHEMBL25707154 | 0.85 | CTSC (0.51) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25707158 | 0.85 | HTR2A (0.50) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25707157 | 0.83 | HTR2A (0.52) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25707149 | 0.83 | HTR2A (0.52) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25707146 | 0.82 | HTR2A (0.57) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25238170 | 0.81 | HTR2A (0.61) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25283339 | 0.80 | HTR2A (0.55) | HTR2AHTR2CTAAR1SMN1; SMN2 | |
| SCHEMBL25283338 | 0.80 | HTR2A (0.55) | HTR2AHTR2CTAAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023115002-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC. (US) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2A 37/4885HTR2C 5/4885TAAR1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.